BXBinhui Xie

Binhui Xie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Binhui Xie has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Ai-Jun Lai

    1 shared publication
  • Binsheng Fu

    Department of Hepatic Surgery and Liver transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, 600# Tianhe Road, Guangzhou, 510630, China.

    1 shared publication
  • Changchang Jia

    Department of Cell-Gene Therapy Translational Medicine Research Center, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

    1 shared publication
  • Heping Li

    Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

    1 shared publication
  • Hui Luo

    School of Basic Medicine, Gannan Medical University

    1 shared publication
  • Hui Tang

    Organ Transplantation Center The Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China

    1 shared publication

Latest Publications

  • Open Access

    Epigenetic silencing of PHYHD1 in hepatocellular carcinoma revealed by integrated multi-omics analysis

    by Tianfu Guo, Yafei Li, Tiansheng He, Hui Luo, Yuwen Liu, Binhui Xie, Zhiping Liu

    Introduction: Hepatocellular carcinoma (HCC) is characterized by extensive epigenetic alterations, particularly DNA methylation. Through integrated multi-omics analysis, we identified methylation-driven genes in HCC, including PHYHD1—a previously understudied candidate whose role in hepatocarcinogenesis remains unexplored. This study aimed to validate and functionally characterize PHYHD1 in HCC. Methods: Five pairs of HCC and adjacent non-tumor tissues were analyzed using whole-genome bisulfite sequencing (WGBS), RNA-seq, and TMT-based proteomics. We identified 97,523 differentially methylated regions (DMRs), 875 differentially expressed genes (DEGs), and 225 differentially expressed proteins (DEPs). PHYHD1 hypermethylation was confirmed by public methylation datasets, and its mRNA/protein expression was validated by RT-qPCR, Western blot, and immunohistochemistry in cell lines, patient tissues (n = 76 pairs), and a DEN/CCl 4 -induced murine HCC model. Functional effects were assessed via in vitro assays (CCK-8, colony formation, flow cytometry) and an in vivo Phyhd1 knockout model. Results: Integration of methylome, transcriptome, and proteome data revealed 19 consistently altered genes enriched in metabolic pathways. PHYHD1 was hypermethylated and downregulated at both mRNA and protein levels in HCC. However, gain- or loss-of-function of PHYHD1 had no detectable effect on proliferation, apoptosis, or tumorigenicity in vitro or in vivo (all P > 0.05). Discussion: Integrated multi-omics analysis identified PHYHD1 as an epigenetically silenced gene in HCC, but functional studies indicate that its silencing does not act as a canonical driver of malignant phenotypes. Instead, PHYHD1 hypermethylation may represent a passenger event or a context-dependent modulator that only exerts effects under specific stress conditions (e.g., hypoxia or metabolic inflammation). These findings suggest that not all methylation-driven genes in HCC are functional drivers, and they highlight the need for further investigation into passenger epigenetic alterations in tumor biology.


  • Open Access

    Minichromosome maintenance 3 promotes hepatocellular carcinoma radioresistance by activating the NF-κB pathway

    by Qing Yang, Binhui Xie, Hui Tang, Wei Meng, Changchang Jia, Xiaomei Zhang, Yi Zhang, Jianwen Zhang, Heping Li, Binsheng Fu

    Hepatocellular carcinoma (HCC) is the most common tumors in the worldwide, it develops resistance to radiotherapy during treatment, understanding the regulatory mechanisms of radioresistance generation is the urgent need for HCC therapy. qRT-PCR, western blot and immunohistochemistry were used to examine MCM3 expression. MTT assay, colony formation assay, terminal deoxynucleotidyl transferase nick end labeling assay and In vivo xenograft assay were used to determine the effect of MCM3 on radioresistance. Gene set enrichment analysis, luciferase reporter assay, western blot and qRT-PCR were used to examine the effect of MCM3 on NF-κB pathway. We found DNA replication initiation protein Minichromosome Maintenance 3 (MCM3) was upregulated in HCC tissues and cells, patients with high MCM3 expression had poor outcome, it was an independent prognostic factor for HCC. Cells with high MCM3 expression or MCM3 overexpression increased the radioresistance determined by MTT assay, colony formation assay, TUNEL assay and orthotopic transplantation mouse model, while cells with low MCM3 expression or MCM3 knockdown reduced the radioresistance. Mechanism analysis showed MCM3 activated NF-κB pathway, characterized by increasing the nuclear translocation of p65, the expression of the downstream genes NF-κB pathway and the phosphorylation of IKK-β and IκBα. Inhibition of NF-κB in MCM3 overexpressing cells using small molecular inhibitor reduced the radioresistance, suggesting MCM3 increased radioresistance through activating NF-κB pathway. Moreover, we found MCM3 expression positively correlated with NF-κB pathway in clinic. Our findings revealed that MCM3 promoted radioresistance through activating NF-κB pathway, strengthening the role of MCM subunits in the tumor progression and providing a new target for HCC therapy.


  • Open Access

    Role of BCAT1 in tumor occurrence and development

    by Ai-Jun Lai, Bin-Hui Xie

    支链氨基酸转移酶1(branched-chain amino acid transaminase 1, BCAT1)是催化支链氨基酸代谢的关键酶. 国内外研究已证实BCAT1在多种恶性肿瘤中呈现高表达, 并提示与肿瘤细胞增殖、转移及侵袭密切相关. 本文拟就BCAT1的理化性质、生物学功能及其与肿瘤发生、发展的相关研究进行简要综述, 为进一步研究BCAT1与恶性肿瘤的关系提供线索.